SAGE Therapeutics Inc
NASDAQ:SAGE

Watchlist Manager
SAGE Therapeutics Inc Logo
SAGE Therapeutics Inc
NASDAQ:SAGE
Watchlist
Price: 8.68 USD Market Closed
Market Cap: 544.9m USD

Operating Margin
SAGE Therapeutics Inc

-430%
Current
-3 516%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-430%
=
Operating Profit
-302.7m
/
Revenue
70.4m

Operating Margin Across Competitors

No Stocks Found

SAGE Therapeutics Inc
Glance View

Market Cap
543.6m USD
Industry
Biotechnology

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2014-07-18. The firm's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.

SAGE Intrinsic Value
17.43 USD
Undervaluation 50%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-430%
=
Operating Profit
-302.7m
/
Revenue
70.4m
What is the Operating Margin of SAGE Therapeutics Inc?

Based on SAGE Therapeutics Inc's most recent financial statements, the company has Operating Margin of -430%.

Back to Top